Genentech Avastin Early Sales Data Suggest Broad Use In Colorectal Cancer
Executive Summary
Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8
You may also be interested in...
Genentech Avastin Account Orders Double, Reorder Rate Improves To 80%
Eighty percent of Genentech's accounts are currently placing reorders for the colorectal cancer therapy Avastin
Genentech Avastin Account Orders Double, Reorder Rate Improves To 80%
Eighty percent of Genentech's accounts are currently placing reorders for the colorectal cancer therapy Avastin
Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says
Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said